Galapagos’ candidate drug, GLPG0187, is an integrin receptor antagonist (IRA) that binds to six integrin receptors known to be present in many metastatic cancers, affording a unique anti-integrin profile. In animal studies, oral administration of GLPG0187 as a single agent has been shown to inhibit multiple processes involved in the spread and growth of metastatic tumors. GLPG0187 therefore offers a new approach to treat metastases, a severe complication of many cancers. In the first-in-human trial, GLPG0187 showed good safety and a promising biomarker profile in healthy volunteers. Based on these results, Galapagos initiated a Phase Ib study in March 2011. In this Phase Ib study, Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients.
For more information, contact Galapagos business development.
Related posters, presentations and publications
Molecular imaging demonstrates GLPG0187, a small-molecule integrin antagonist, binds to RGD-integrin receptors in vivo and is efficacious in tumor and metastasis models
Pujuguet P, Berrocal E, Heckmann B, Wigerinck P, Lorenzon G, Clément-Lacroix P, Bormans G, Deroose
EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer
GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTx levels in a single ascending dose study
Vanhoutte F, Lorenzon G, Gheyle L, Vets E, Namour F, Pujuguet P, Clément-Lacroix P, Blockhuys C, Wigerinck P
Knowledge for Growth
GLPG0187 inhibits progression of established bone metastasis and achieves maximum efficacy when combined with standard-of-care metastatic breast cancer treatments
Clément-Lacroix P, Berrocal E, Heckmann B, Wigerinck P, Lorenzon G, Pujuguet P
International Conference on Cancer-Induced Bone Disease